Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib

Nephrology Dialysis Transplantation

Volumn 24, Issue 2, 2009, Pages 682-685

  Bollée, Guillaume ^a,b   Patey, Natacha ^a,b   Cazajous, Géraldine ^a,b   Robert, Caroline ^a,b,c   Goujon, Jean Michel ^d   Fakhouri, Fadi ^a,b   Bruneval, Patrick ^e   Noël, Laure Hélène ^a,b   Knebelmann, Bertrand ^a,b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d POITIERS UNIVERSITY HOSPITAL   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Sunitinib; Thrombotic microangiopathy; VEGF

Indexed keywords

AMILORIDE; BEVACIZUMAB; DILTIAZEM; DOXORUBICIN; IRBESARTAN; PACLITAXEL; SUNITINIB; VASCULOTROPIN;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE SEVERITY; FEMALE; HIDRADENOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; KIDNEY BIOPSY; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROTEINURIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADENOMA, SWEAT GLAND; ADULT; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INDOLES; KIDNEY; PROTEIN KINASE INHIBITORS; PYRROLES; SKIN NEOPLASMS; THROMBOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 58449096748     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn657     Document Type: Article

References (16)

1. Zhu X, Wu S, Dahut WL et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007; 49: 186-193
2. Eremina V, Jefferson JA, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358: 1129-1136
3. Roncone D, Satoskar A, Nadasdy T et al. Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma. Nat Clin Pract Nephrol 2007; 3: 287-293
4. Kapiteijn E, Brand A, Kroep J et al. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol 2007; 18: 1745-1747
5. Obhrai JS, Patel TV, Humphreys BD. The case/progressive hypertension and proteinuria on anti-angiogenic therapy. Kidney Int 2008; 74: 685-686
6. Patel TV, Morgan JA, Demetri GD et al. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst 2008; 100: 282-284
7. Raife TJ, Lager DJ. Chronic thrombotic microangiopathy associated with antineoplastic therapy with minimal hematologic effects. Mayo Clin Proc 2002; 77: 323-328
8. Frangie C, Lefaucheur C, Medioni J et al. Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol 2007; 8: 177-178
9. Izzedine H, Brocheriou I, Deray G et al. Thrombotic microangiopathy and anti-VEGF agents. Nephrol Dial Transplant 2007; 22: 1481-1482
10. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 2004; 65: 2003-2017
11. Scappaticci FA, Skillings JR, Holden SN et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99: 1232-1239
12. Sane DC, Anton L, Brosnihan KB. Angiogenic growth factors and hypertension. Angiogenesis 2004; 7: 193-201
13. Fakhouri F, Fremeaux-Bacchi V. Does hemolytic uremic syndrome differ from thrombotic thrombocytopenic purpura? Nat Clin Pract Nephrol 2007; 3: 679-687
14. Fakhouri F, Jablonski M, Lepercq J et al. Membrane cofactor protein and Factor I mutations in patients with HELLP syndrome. Blood 2008 (in press)
15. Levine RJ, Maynard SE, Qian C et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672-683
16. Van Heeckeren WJ, Ortiz J, Cooney MM et al. Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker? J Clin Oncol 2007; 25: 2993-2995